Kiwi Biosciences
Patent-pending enzymes to break down common dietary triggers
About Kiwi Biosciences
Kiwi Biosciences can help 18M Americans suffering from Irritable Bowel Syndrome (IBS) enjoy a normal meal without running to the bathroom two hours later. We develop novel, patent-pending enzymes that break down common digestive triggers in food.
Company details
Funding
Total raised
$1.6M
Last stage
Seed
Investors
Founders
Anjie Liu
Harvard alumna (physics & comparative literature, 2017). Personal IBS patient who developed FODZYME. Named to Forbes 30 Under 30 Local Class of 2023.
LinkedInDavid Hachuel
MPH in Epidemiology from Harvard School of Public Health; Master's in Computer and Information Science from Cornell. Previously co-founder & CEO of auggi.ai (acquired by Seed Health).
David Hachuel Gurska
Formerly co-founder and CEO at auggi.ai, a digital gut health coach for patients with Irritable Bowel Syndrome (IBS). auggi was recently acquired by Seed Health. Completed my MPH in Epidemiology at the Harvard School of Public Health and a Master's in Computer and Information Science at Cornell University.
What happens next.
No applications, no recruiter spam. Just the intro.
Confirm the fit
A few questions to make sure this role is the right shape for you. Two minutes.
I pitch you to the company
I write the intro, send it to the founder, and handle the back-and-forth.
A meeting lands on your calendar
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.